Join

Compare · NVO vs PRTA

NVO vs PRTA

Side-by-side comparison of Novo Nordisk A/S (NVO) and Prothena Corporation plc (PRTA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and PRTA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $191.82B, about 416.8x PRTA ($460.2M).
  • Over the past year, NVO is down 44.4% and PRTA is up 65.0% - PRTA leads by 109.4 points.
  • NVO has been more active in the news (8 items in the past 4 weeks vs 3 for PRTA).
  • NVO has more recent analyst coverage (25 ratings vs 22 for PRTA).
PerformanceNVO-44.38%PRTA+64.99%
2025-06-09+0.00%2026-06-08
MetricNVOPRTA
Company
Novo Nordisk A/S
Prothena Corporation plc
Price
$41.94-2.34%
$8.70-0.91%
Market cap
$191.82B
$460.2M
1M return
-8.33%
-16.83%
1Y return
-44.38%
+64.99%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
News (4w)
8
3
Recent ratings
25
22
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

PRTA

Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.

Latest NVO

Latest PRTA